• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Skip Standards and indicators submenu

    Quality standards

    Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.

    View our quality standards

    • How to use our quality standards
    • The timeline for developing quality standards
    • Help us develop quality standards
    • Selecting and prioritising quality standards topics
    • About quality standards

    Indicators

    Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.

    View list of indicators

    • Learn about the committee that develops indicators
    • About indicators
  • Skip Life sciences submenu

    Life Sciences

    We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.

    View life sciences

    Get support from NICE

    NICE Advice service

    Trusted, unrivalled expertise.

    Make an enquiry

    Contact us to discuss your requirements.

    Innovative Licensing and Access Pathway (ILAP)

    Streamlining patient access to safe, financially sustainable and innovative medicines.

    Learn how we evaluate technologies

    Health technology evaluation and topic selection manuals

    Updated manuals for methods, processes and topic selection.

    Digital health technologies

    Accelerating our efforts to deliver innovation to the health and care system.

    Evidence standards framework

    Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.

    Our guidance programmes

    Ensuring new technologies are clinically effective and offer economic value.

    Register your product

    Non-pharmaceutical

    NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.

    Pharmaceutical

    UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.

    Find published and proposed evaluations

    Diagnostics

    Guidance on measurements and tests used to evaluate a patient's condition.

    Medical technologies

    Guidance on medical technologies put forward to NICE by manufacturers.

    Technology appraisals

    Guidance on new and existing medicines and treatments in the NHS.

    Highly specialised technologies

    Guidance on the use of highly specialised medicines and treatments.

  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Skip About submenu

    About

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

    Explore about

    Our programmes

    Learn about the information we produce.

    • Guidance
    • Advice
    • Quality standards
    • Indicators
    • Digital health
    • Topic selection

    Get involved

    • Understand how decisions are made:

      Attend a committee meeting
    • Comment on draft guidance:

      Guidance in consultation
    • Be part of a guidance committee:

      Join a committee
    • Help develop our products:

      Register as a stakeholder
    • Putting you at the heart of our work:

      Public involvement

    What we do

    • Social care
    • Life sciences
    • NICE international
    • Patient safety
    • Shared decision making
    • View all What we do

    Into practice

    • Social care quick guides
    • Measuring the use of NICE guidance
    • Resource planner
    • View all Into practice

    Who we are

    • The board
    • The NICE strategy 2021 to 2026
    • Corporate publications
    • View all Who we are

    • Contact us
    • Jobs

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home

Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template

  • NICE process and methods
  • Reference number: PMG24
  • Published:  08 January 2015
  • Last updated:  03 December 2024
  • Process
  • Tools and resources
Download (PDF)
  • Overview
  • Instructions for companies
  • 1 Decision problem, description of the technology and clinical care pathway
  • 2 Clinical effectiveness
  • 3 Cost effectiveness
  • 4 References
  • 5 Appendices
  • Appendix A: Summary of product characteristics (SmPC) and UK public assessment report
  • Appendix B: Identification, selection and synthesis of clinical evidence
  • Appendix C: Subgroup analysis
  • Appendix D: Adverse reactions
  • Appendix E: Published cost-effectiveness studies
  • Appendix F: Health-related quality-of-life studies
  • Appendix G: Cost and healthcare resource identification, measurement and valuation
  • Appendix H: Clinical outcomes and disaggregated results from the model
  • Appendix I: Price details of treatments included in the submission
  • Update information

Appendix F: Health-related quality-of-life studies

Describe how systematic searches for relevant health-related quality-of-life data were done. Consider published and unpublished studies, including any original research commissioned for the technology. Provide the rationale for terms used in the search strategy and any inclusion and exclusion criteria used. The search strategy used should be provided in the appendix.

Tabulate the details of the studies in which health-related quality of life was measured. Include the following, but note that this list is not exhaustive:

  • population in which health effects were measured

  • information on recruitment (for example, participants of a clinical trial, approximations from clinical experts, utility elicitation exercises including members of the general public or patients)

  • interventions and comparators

  • sample size

  • response rates

  • description of health states

  • adverse reactions

  • appropriateness of health states given the condition and treatment pathway

  • method of elicitation

  • method of valuation

  • mapping

  • uncertainty around values

  • consistency with reference case.

See section 3.4.3.


Next page Appendix G: Cost and healthcare resource identification, measurement and valuation Previous page Appendix E: Published cost-effectiveness studies
  • Guidance
  • Standards and indicators
  • Life sciences
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Knowledge resources
  • About NICE
  • Into practice
  • Get involved with NICE
  • Jobs
  • News
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.